Exome sequencing shows same pattern of clonal tumor mutational burden, intratumor heterogenicity and clonal neoantigen between autologous tumor and Vigil product

Frontage Laboratories has validated an exome sequencing assay that demonstrates high concordance between Gradalis Inc.’s Vigil® product and the originating autologous tumor—preserving clonal tumor mutational burden, neoantigen load, and intratumor heterogeneity. With correlation scores above 0.87, our platform confirms the fidelity of personalized cancer vaccines. This service empowers immunotherapy developers with reliable tumor profiling to support product validation, patient selection, and next-generation cancer vaccine strategies.

"*" indicates required fields

Comments

This field is for validation purposes and should be left unchanged.

First Name*

Last Name*

Company*

State*